on a consistent basis to reflect the classification of Opella as a discontinued operation.
(b)
This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.